Phesgo and Tecentriq Performance and Approvals

Spinal Muscular Atrophy: Evrysdi market leader in US and Japan Increasing penetration in treatment-naive patient segment CHFM 450 400 350 300 250 +189% 200 150 100 50 Q1 21 US CER=Constant Exchange Rates Q122 Europe International Japan Q1 update YoY CER growth +62% Q123 • >8,500 patients treated worldwide; retention rate in first 12 months of ~90% globally • US: Growth driven by switch and naive patient starts, including patients <2 months old • Ex-US: Continued strong growth and share gains in all major markets • ⚫ Ph II/III (SUNFISH) 4year data presented at MDA 2023 Outlook 2023 • Continued growth and market share gains • EU: Label extension (<2 months old) based on Ph II (RAINBOWFISH) expected Roche 28

View entire presentation